Argentus Capital Management’s Teva Pharmaceuticals TEVA Stock Holding History

Argentus Capital Management’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-11,537	Closed	-$531K	–	450
2016 Q3	$531K	Buy	11,537 +5,427	+89%	+$283K	0.19%	130
2016 Q2	$307K	Buy	6,110 +3,408	+126%	+$181K	0.13%	241
2016 Q1	$145K	Buy	2,702 +579	+27%	+$34K	0.05%	360
2015 Q4	$139K	Sell	2,123 -41,719	-95%	-$2.58M	0.04%	323
2015 Q3	$2.48M	Buy	43,842 +670	+2%	+$43.4K	0.37%	67
2015 Q2	$2.55M	Buy	43,172 +1,731	+4%	+$107K	0.39%	69
2015 Q1	$2.58M	Buy	41,441 +1,416	+4%	+$82.3K	0.41%	64
2014 Q4	$2.3M	Sell	40,025 -976	-2%	-$54.4K	0.39%	75
2014 Q3	$2.2M	Buy	41,001 +94	+0.2%	+$4.98K	0.35%	75
2014 Q2	$2.14M	Sell	40,907 -1,357	-3%	-$69.4K	0.56%	36
2014 Q1	$2.23M	Buy	42,264 +2,187	+5%	+$101K	0.54%	30
2013 Q4	$1.61M	Buy	40,077 +1,108	+3%	+$43.6K	0.34%	47
2013 Q3	$1.47M	Buy	38,969 +2,728	+8%	+$106K	0.34%	49
2013 Q2	$1.42M	Buy	+36,241	New	+$1.41M	0.34%	59

Other funds holding TEVA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $30.5B AUM 29.95% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

HCM

Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Nordea Investment Management Stockholm, Sweden $107B AUM 24.58% 1-Year Est. Return

Argentus Capital Management's TEVA Position: Q4 2016 in Review

Argentus Capital Management sold out of Teva Pharmaceuticals (TEVA) in Q4 2016, closing a stake of 11,537 shares — an estimated $531K sold.

Argentus Capital Management first reported a position in TEVA in Q2 2013 and held it in 14 quarters. The position peaked at $2.58M in Q1 2015. 737 funds tracked by Wall St. Rank hold TEVA as of Q4 2016.

Argentus Capital Management reported no remaining Teva Pharmaceuticals position as of Q4 2016 after selling out during the quarter.
Argentus Capital Management sold 11,537 Teva Pharmaceuticals shares in Q4 2016, an estimated $531K.
Argentus Capital Management first reported a position in Teva Pharmaceuticals in Q2 2013 and held it in 14 quarters.
Argentus Capital Management's Teva Pharmaceuticals position peaked at $2.58M in Q1 2015.
737 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q4 2016.

Based on Argentus Capital Management's 13F filing for Q4 2016.